The contract research organization (CRO), Altasciences, will provide its clinical pharmacology, first-in-human and proof-of-concept trials, program management and other full-service solutions to support early phase clinical services for WIND, WuXi AppTec’s investigational new drug (IND) platform.
The platform combines CRO services with program management and regulatory support for IND applications.
Per the agreement, Altasciences will provide full-service early phase clinical solutions to the partnership to support the addition of the IND platform. Altasciences has agreed to provide clinical pharmacology, first-in-human and proof-of-concept trials, program management, and data management, among other services to streamline early phase clinical processes for WuXi’s IND programs.
A spokesperson for WuXi Apptec told us, “The objective of WIND is to support the full scope of drug development programs, from IND-enabling studies to document preparation and submission. By partnering with Altasciences, WuXi can be more flexible with scheduling multiple components of the drug development process from lead candidate selection through to proof of concept, therefore, accelerating the IND process.”
WuXi Clinical, the clinical CRO arm of WuXi AppTec will manage the partnership between the two companies. The WuXi AppTec spokesperson told us the clinical arm had been looking to partner in North America in an aim to complement its current Phase I offering and support the IND platform.
Additionally, a number of senior executives at Altasciences have previously worked at WuXi, which the company believes will build a true collaboration, according to the WuXi spokesperson.
